Atlas Trials

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Clinical trial NCT06782932 · RECRUITING

Trial details

NCT number
NCT06782932
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2025-05-27
Primary completion
2028-12-01
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.